You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 2, February 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  The Cutting Edge: Challenges in Medical and Surgical Therapeutics
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Laser Surgery
 •Alert me on articles by topic

Lupus Miliaris Disseminatus Faciei

Treatment With the 1450-nm Diode Laser

Ming H. Jih, MD, PhD; Paul M. Friedman, MD; Arash Kimyai-Asadi, MD; Edward S. Friedman, MD; Sharon R. Hymes, MD; Leonard H. Goldberg, MD
From the DermSurgery Associates (Drs Jih, P. M. Friedman, Kimyai-Asadi, and Goldberg), The University of Texas School of Medicine (Dr P. M. Friedman), Baylor College of Medicine (Dr E. S. Friedman), and The University of Texas M. D. Anderson Cancer Center (Drs Hymes and Goldberg), Houston.

Arch Dermatol. 2005;141:143-145.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF A CASE

A 35-year-old white woman presented with a 3-year history of brown-red papules on her forehead, cheeks, nose, and chin (Figure 1). The lesions were initially treated with topical metronidazole cream, without improvement. A biopsy specimen revealed epithelioid cell granulomas with central necrosis, consistent with a diagnosis of lupus miliaris disseminatus faciei (Figure 2). Oral minocycline therapy (100 mg twice a day) was initiated but was discontinued shortly thereafter because of drug-induced urticaria. Subsequent courses of oral erythromycin (500 mg twice daily for 1 month) and oral isotretinoin (1 mg/kg per day for 2 months) were ineffective. Because of the continued formation of new inflammatory lesions, oral prednisone therapy (40 mg/d) was initiated, but 1 month later there was still no improvement in . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT

AUTHOR INFORMATION







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.